In This Article:
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
In a little more than a week’s time, a drug developed by a small psychedelics company was able to significantly curb hard-to-treat depression in a mid-stage clinical trial.
That’s according to high-level results announced Monday. The trial recruited 81 people with treatment-resistant depression and evaluated them via a widely used, 60-point scale where larger scores mean more severe depressive symptoms. The drug, from Ireland-based GH Research, hit the study’s main goal by showing that participants taking it had their scores drop 15.5 points more than those who were given a placebo.
GH Research said its drug was well-tolerated. No serious adverse events had been reported as of Jan. 22. All “treatment-emergent adverse events” were mild or moderate, and investigators found no evidence the drug led to flashbacks, suicidal thoughts or behavior, or changes in heart activity. Almost all participants were discharge-ready within an hour of getting their last doses.
Additionally, GH Research called the drug “ultra-rapid,” providing relief just eight days into treatment. By that time, 58% of patients in the drug arm were in remission, compared with 0% in the placebo group. Among 54 patients who then completed an “extension” portion of the study — in which everyone knowingly got the drug — the remission rate was 78% at the six-month mark.
“A novel treatment with such a large and rapid effect, particularly one that may require only infrequent, short 1-3 hours clinic visits, has the potential to be a practice changing treatment,” Michael Thase, a psychiatry professor at University of Pennsylvania and a GH Research scientific adviser, said in a statement from the company.
The drug is an inhalable form of mebufotenin, one member in a diverse family of molecules that also includes serotonin, melatonin and a psychedelic chemical found in some mushrooms. GH Research studied it in bipolar II disorder as well, and has a different, injectable version of it that went through a small trial of healthy volunteers.
The newly released results look “highly compelling” and the “best-in-class” for a psychedelic targeting treatment-resistant depression, according to Paul Matteis, an analyst at the investment bank Stifel. While the experiment was not large, and the lack of any signal in the placebo group could be from patients deciphering what arm they were assigned to, Matteis still thinks the study was well run and had no oddities or red flags.